IDEX Corporation is expected to report Q3 2026 revenue of $919.4 million and adjusted EPS of $2.23, while its current price of $229.05 remains below the consensus analyst target of $256.57.
Investors are specifically monitoring the Health & Science Technologies (HST) segment, which is projected to drive growth through its exposure to the semiconductor and AI data center markets.
The company recently increased its full-year organic growth guidance to 5–6% following record-breaking order volume in the prior quarter. Analysts expect these robust backlogs to mitigate potential headwinds in the Fire & Safety segment as IDEX continues its acquisition-led expansion strategy.